타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials |
|---|---|
Overview Program | Tezspire (tezepelumab) |
Overview Company | AstraZeneca / Amgen |
Overview Modality | ANTIBODY |
Overview Target | TSLP (thymic stromal lymphopoietin) |
Overview Indication | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. |
Positioning Known limitation | Non-inflammatory structural airway disease does not respond to cytokine blockade. |
Positioning Development positioning | Add-on maintenance |
MoA Mechanism | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. |
MoA Biomarker | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. |
Toxicology CRS | N/A |
Clinical Safety signal | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials |
|---|---|
Overview Program | Tezspire (tezepelumab) |
Overview Company | AstraZeneca / Amgen |
Overview Modality | ANTIBODY |
Overview Target | TSLP (thymic stromal lymphopoietin) |
Overview Indication | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. |
Positioning Known limitation | Non-inflammatory structural airway disease does not respond to cytokine blockade. |
Positioning Development positioning | Add-on maintenance |
MoA Mechanism | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. |
MoA Biomarker | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. |
Toxicology Species | Cynomolgus monkey |
Toxicology Major finding | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. |
Toxicology CRS | N/A |
Clinical Safety signal | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교